Table 3.
Immune cell phenotypes of primary tumor and corresponding lesions in relation to platinum-sensitivity.
| PT | OM/PT | PE/PT | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Platinum-Sensitivity * | Platinum-Sensitivity * | Platinum-Sensitivity * | |||||||||||||
| n | Red | Full | p # | n | Red | Full | p # | n | Red | Full | p # | ||||
| CD45 stromal | 42 | 1 | 19 | 0.350 | 12 | 0.250 | |||||||||
| Low | 4 | 8 | OM ≤ PT | 2 | 7 | PE ≤ PT | 2 | 9 | |||||||
| High | 10 | 20 | OM > PT | 5 | 5 | PE > PT | 1 | 0 | |||||||
| CD45 intratumoral | 42 | 1 | 19 | 1 | 12 | 1 | |||||||||
| Low | 8 | 15 | OM ≤ PT | 6 | 11 | PE ≤ PT | 3 | 8 | |||||||
| High | 6 | 13 | OM > PT | 1 | 1 | PE > PT | 0 | 1 | |||||||
| CD3 stromal | 42 | 1 | 19 | 1 | 12 | 0.523 | |||||||||
| Low | 8 | 16 | OM ≤ PT | 1 | 3 | PE ≤ PT | 2 | 3 | |||||||
| High | 6 | 12 | OM > PT | 6 | 9 | PE > PT | 1 | 6 | |||||||
| CD3 intratumoral | 42 | 0.057 | 19 | 0.633 | 12 | 1 | |||||||||
| Low | 11 | 13 | OM ≤ PT | 2 | 6 | PE ≤ PT | 2 | 4 | |||||||
| High | 3 | 15 | OM > PT | 5 | 6 | PE > PT | 1 | 5 | |||||||
| CD8 stromal | 42 | 0.748 | 19 | 1 | 12 | 0.523 | |||||||||
| Low | 7 | 16 | OM ≤ PT | 2 | 3 | PE ≤ PT | 1 | 6 | |||||||
| High | 7 | 12 | OM > PT | 5 | 9 | PE > PT | 2 | 3 | |||||||
| CD8 intratumoral | 42 | 1 | 19 | 0.656 | 12 | 0.045 | |||||||||
| Low | 9 | 18 | OM ≤ PT | 2 | 5 | PE ≤ PT | 3 | 2 | |||||||
| High | 5 | 10 | OM > PT | 5 | 7 | PE > PT | 0 | 7 | |||||||
| PD-1 stromal | 42 | 0.283 | 19 | 1 | 12 | 0.045 | |||||||||
| Low | 12 | 19 | OM ≤ PT | 2 | 4 | PE ≤ PT | 0 | 7 | |||||||
| High | 2 | 9 | OM > PT | 5 | 8 | PE > PT | 3 | 2 | |||||||
| PD-1 intratumoral | 42 | 0.738 | 19 | 1 | 12 | 1 | |||||||||
| Low | 10 | 18 | OM ≤ PT | 5 | 8 | PE ≤ PT | 3 | 7 | |||||||
| High | 4 | 10 | OM > PT | 2 | 4 | PE > PT | 0 | 2 | |||||||
| PD-L1 Positivity | 42 | 1 | 19 | 0.603 | 12 | 1 | |||||||||
| No | 5 | 10 | OM ≤ PT | 5 | 10 | PE ≤ PT | 2 | 7 | |||||||
| Yes | 9 | 18 | OM > PT | 2 | 2 | PE > PT | 1 | 2 | |||||||
n: number of patients, red: reduced, PD-1: programmed cell-death protein 1, PD-L1: programmed cell-death ligand 1. * Platinum-sensitivity was defined as follows: reduced (relapse ≤ 12 months after chemotherapy) and full (relapse > 12 months after chemotherapy), # p-value calculated by Fisher’s exact two-tailed test.